ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biomatter has raised about $7 million in a seed funding round led by Inventure and UVC Partners. Scientists from the Lithuanian firm published a paper in Nature Machine Intelligence in 2019 detailing functional enzymes created with generative artificial intelligence, which the company claims were the first of their kind (DOI: 10.1038/s42256-021-00310-5). Biomatter says it will put the funding toward further development of its method of creating de novo enzymes. While other AI-based protein design methods rely on making changes to existing proteins, the company says it has a “bottom-up” approach.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter